We investigated whether pretreatment with the neurotransmitter/neuromodulator agmatine (decarboxylated L-arginine) affected methamphetamine (METH)-induced hyperlocomotion and stereotypy in male ICR mice. Agmatine pretreatment alone had no effects on locomotion or stereotypy, but it produced a dose-dependent attenuation of locomotion and the total incidence of stereotyped behavior induced by a low dose of METH (5 mg/kg). The stereotypy induced by this dose was predominantly characterized by stereotyped sniffing. By contrast, agmatine did not affect the total incidence of stereotypy induced by a higher dose of METH (10 mg/kg). However, the nature of stereotypy induced by this dose of METH was substantially altered; agmatine pretreatment significantly reduced stereotyped biting but significantly increased stereotyped sniffing and persistent locomotion. Agmatine pretreatment therefore appears to produce a rightward shift in the dose-response curve for METH. Pretreatment of mice with piperazine-1-carboxamidine (a putative agmatinase inhibitor) had no effect on locomotion or stereotypy induced by a low dose of METH, suggesting that endogenous agmatine may not regulate the METH action.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/FBP.0000000000000030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibitory effects of the selective μ-opioid receptor antagonist UD-030 on methamphetamine-induced conditioned place preference.
Neuropsychopharmacol Rep
March 2025
Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Although methamphetamine (METH) and other addictive substance use disorders are a major social problem worldwide, appropriate pharmacotherapies have not yet been discovered. Subtype-nonselective opioid receptor antagonists, such as naltrexone (NTX), have been reported to suppress METH addiction, but unclear are the opioid receptor subtypes that are involved in this beneficial effect. To clarify the role of μ-opioid receptors (MOPs), we examined effects of the novel nonpeptidic MOP-selective antagonist UD-030 on the acquisition and expression of METH-induced conditioned place preference (CPP) using behavioral tests in C57BL/6J mice.
View Article and Find Full Text PDFCannabidiol Plays a Modulatory Function on the Methamphetamine-Induced Reward Through Hippocampal D2-Like Dopamine Receptors.
Neurochem Res
November 2024
Neuroscience Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, P.O. Box: 19615-1178, Tehran, Iran.
Methamphetamine (METH), a stimulant that is extremely addictive, directly affects the central nervous system. METH's abuse and consumption are directly linked to mental illnesses, psychosis, and behavioral and cognitive impairments. It may disrupt the reward system and dopaminergic transmission.
View Article and Find Full Text PDFTargeting retrieval of methamphetamine reward memory in the context of REM sleep deprivation: Age-dependent role of GABA receptors.
Pharmacol Biochem Behav
December 2024
Center for Excellence in Brain Science and Intelligence Technology (Institute of Neuroscience), Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai, 200031, P.R.China.
Article Synopsis
- GABA receptors are linked to drug addiction, sleep issues, and aging, but their interrelationships are not well researched; this study focuses on how blocking these receptors influences methamphetamine (METH) reward memory in sleep-deprived rats.
- Adult and adolescent male Wistar rats underwent seven days of rapid-eye movement sleep deprivation and then were conditioned with METH before testing their memory retrieval after administering the GABA receptor agonist baclofen.
- Baclofen reduced METH reward memory retrieval in both age groups, with stronger effects seen in adolescents, and the high dose lowered GABA overexpression in adolescent rats, suggesting age and sleep deprivation play significant roles in addiction mechanisms.
5-HT receptors in the nucleus accumbens constrain the rewarding effects of MDMA.
bioRxiv
October 2024
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305.
MDMA is a promising adjunct to psychotherapy and has well-known abuse liability, although less than other amphetamine analogs. While the reinforcing dopamine (DA)-releasing properties of MDMA are on par with methamphetamine (METH), MDMA is a far more potent serotonin (5-HT) releaser, via the 5-HT transporter (SERT). MDMA-mediated 5-HT release in a major reward center, the nucleus accumbens (NAc), drives prosocial behaviors via 5-HTR activation.
View Article and Find Full Text PDFA methamphetamine vaccine using short monoamine and diamine peptide linkers and poly-mannose.
Bioorg Med Chem
November 2024
Immunology Program, Australian Institute for Musculoskeletal Sciences (AIMSS), Melbourne, VIC 3021, Australia; School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia. Electronic address:
Methamphetamine (METH) substance use disorder is a long-standing and ever-growing public health concern. Efforts to develop successful immunotherapies are ongoing with vaccines that generate strong antibody responses are an area of significant research interest. Herein, we describe the development of a METH Hapten conjugate vaccine comprised of either two short-length peptides as linkers and mannan as an immunogenic delivery carrier.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!